Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-04

AUTHORS

Giuseppe Gullo, Daniela Bettio, Valter Torri, Giovanna Masci, Piermario Salvini, Armando Santoro

ABSTRACT

To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC. More... »

PAGES

179

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y

DOI

http://dx.doi.org/10.1007/s10637-008-9155-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016696899

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18663410


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Amplification", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, erbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Situ Hybridization, Fluorescence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Predictive Value of Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gullo", 
        "givenName": "Giuseppe", 
        "id": "sg:person.01223342332.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223342332.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Laboratory of Cytogenetics, Istituto Clinico Humanitas IRCCS, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bettio", 
        "givenName": "Daniela", 
        "id": "sg:person.0726433703.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726433703.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mario Negri Institute for Pharmacological Research", 
          "id": "https://www.grid.ac/institutes/grid.4527.4", 
          "name": [
            "Clinical Oncology Research Unit, Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Torri", 
        "givenName": "Valter", 
        "id": "sg:person.01213013520.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213013520.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masci", 
        "givenName": "Giovanna", 
        "id": "sg:person.01203725612.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203725612.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology Unit, Cliniche Gavazzeni, Bergamo, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salvini", 
        "givenName": "Piermario", 
        "id": "sg:person.01357677760.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357677760.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Santoro", 
        "givenName": "Armando", 
        "id": "sg:person.01277354144.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277354144.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3816/cbc.2005.n.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001198940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.173", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003035955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cbc.2001.n.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003466394"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.copbio.2007.11.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007493316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012929330", 
          "https://doi.org/10.1038/sj.bjc.6602926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012929330", 
          "https://doi.org/10.1038/sj.bjc.6602926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.8957", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019255637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2006.11.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022644824"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.2775", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026719751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdj905", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031702252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200103153441101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031768583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2007.08.030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034133737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006111117877", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037590396", 
          "https://doi.org/10.1023/a:1006111117877"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/01.mp.0000052102.90815.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043809974", 
          "https://doi.org/10.1097/01.mp.0000052102.90815.82"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl475", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046368550"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djk134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047572985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djk134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047572985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006262324959", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047763314", 
          "https://doi.org/10.1023/a:1006262324959"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049278910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049548242"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.3798106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062621480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.20.3.719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064202789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.20.3.719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083941918"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-04", 
    "datePublishedReg": "2009-04-01", 
    "description": "To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-008-9155-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "name": "Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer", 
    "pagination": "179", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-008-9155-y"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4f8dd6d38b5348ae802a862450e05f0418acb3e4f2fc9d4658c21e7bd7bcaad5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016696899"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18663410"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-008-9155-y", 
      "https://app.dimensions.ai/details/publication/pub.1016696899"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56164_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-008-9155-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      21 PREDICATES      66 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-008-9155-y schema:about N00fc1f3e20334f8eb879bef0f59ce7c4
2 N086c1f98aa084e0b919c68cc9c83f1f8
3 N119b242465294960a15574ccd75fe037
4 N2109731ca27f471a814ba7dacd78294b
5 N3012ea1b0b9e45249e91efddf4a783d0
6 N6813fec3f909465c8ea6cac4b0c2d119
7 N6d170913c20a446697255a67774e8c4f
8 N6e4dc9ec22e84ed1a6dd10123c9122c6
9 N77dfb9e9520744e095403e785b4725e0
10 N8a03979d391c473abc5143723d06f75a
11 N8dea9f8d71974a229780889e8f241634
12 Na36f02d5f1df4d01a9204717d3826e22
13 Nacf435fc173d46ae908764f8de9ee683
14 Nb23213fe1b914becb1a28959b3f9d48f
15 Nc8b9b95ebf834fdb8e9eae11f1105630
16 Nfe7bc5d1dd1b425cb4b58825c8a2f7a7
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Nb16ce7e4384c47b0b70b045a2695363e
20 schema:citation sg:pub.10.1023/a:1006111117877
21 sg:pub.10.1023/a:1006262324959
22 sg:pub.10.1038/sj.bjc.6602926
23 sg:pub.10.1097/01.mp.0000052102.90815.82
24 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
25 https://doi.org/10.1016/j.ccr.2007.08.030
26 https://doi.org/10.1016/j.copbio.2007.11.004
27 https://doi.org/10.1016/j.ejca.2006.11.019
28 https://doi.org/10.1056/nejm200103153441101
29 https://doi.org/10.1093/annonc/mdj905
30 https://doi.org/10.1093/annonc/mdl475
31 https://doi.org/10.1093/jnci/djk134
32 https://doi.org/10.1126/science.3798106
33 https://doi.org/10.1158/1078-0432.ccr-06-1304
34 https://doi.org/10.1200/jco.20.3.719
35 https://doi.org/10.1200/jco.2002.20.3.719
36 https://doi.org/10.1200/jco.2005.04.173
37 https://doi.org/10.1200/jco.2006.09.2775
38 https://doi.org/10.1200/jco.2007.14.8957
39 https://doi.org/10.3816/cbc.2001.n.017
40 https://doi.org/10.3816/cbc.2005.n.026
41 schema:datePublished 2009-04
42 schema:datePublishedReg 2009-04-01
43 schema:description To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC.
44 schema:genre research_article
45 schema:inLanguage en
46 schema:isAccessibleForFree true
47 schema:isPartOf N9928f03e0aa2452291acf472c84aac89
48 Ne6d632b2dbf74317ba30303928cbef98
49 sg:journal.1094201
50 schema:name Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
51 schema:pagination 179
52 schema:productId N1b3841f938c04d44bb1083f490151422
53 N553f4f915c8a4940981d1ff6c9edfa2e
54 N7885646763ed40fe850e3cf87306570e
55 Nb2ca9bf74355491fab28191b775977de
56 Nc49841940fa046efbcac4fe0b77fbb27
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016696899
58 https://doi.org/10.1007/s10637-008-9155-y
59 schema:sdDatePublished 2019-04-15T09:13
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher Nd040af92174a449bac85a7160fdff292
62 schema:url https://link.springer.com/10.1007%2Fs10637-008-9155-y
63 sgo:license sg:explorer/license/
64 sgo:sdDataset articles
65 rdf:type schema:ScholarlyArticle
66 N00fc1f3e20334f8eb879bef0f59ce7c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Antibodies, Monoclonal, Humanized
68 rdf:type schema:DefinedTerm
69 N086c1f98aa084e0b919c68cc9c83f1f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Adult
71 rdf:type schema:DefinedTerm
72 N111243f8825a4f5a9789202f52d54102 rdf:first sg:person.01203725612.04
73 rdf:rest N9b11b37a5bfb4e1389def6c67ad7fb92
74 N119b242465294960a15574ccd75fe037 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Female
76 rdf:type schema:DefinedTerm
77 N11dcf2ccb0d642cb9a23a5f57870ad9c rdf:first sg:person.0726433703.81
78 rdf:rest N82b4f42e847d432bbe59d351e8941b99
79 N1b3841f938c04d44bb1083f490151422 schema:name dimensions_id
80 schema:value pub.1016696899
81 rdf:type schema:PropertyValue
82 N2109731ca27f471a814ba7dacd78294b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Genes, erbB-2
84 rdf:type schema:DefinedTerm
85 N236a578589d64f659d6d12fbefee0c5f schema:name Medical Oncology Unit, Cliniche Gavazzeni, Bergamo, Italy
86 rdf:type schema:Organization
87 N3012ea1b0b9e45249e91efddf4a783d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Antibodies, Monoclonal
89 rdf:type schema:DefinedTerm
90 N553f4f915c8a4940981d1ff6c9edfa2e schema:name pubmed_id
91 schema:value 18663410
92 rdf:type schema:PropertyValue
93 N6813fec3f909465c8ea6cac4b0c2d119 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Disease-Free Survival
95 rdf:type schema:DefinedTerm
96 N6d170913c20a446697255a67774e8c4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Predictive Value of Tests
98 rdf:type schema:DefinedTerm
99 N6e4dc9ec22e84ed1a6dd10123c9122c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Humans
101 rdf:type schema:DefinedTerm
102 N6fb3ce40dd1e45038783e145198c39f1 rdf:first sg:person.01277354144.26
103 rdf:rest rdf:nil
104 N77dfb9e9520744e095403e785b4725e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name In Situ Hybridization, Fluorescence
106 rdf:type schema:DefinedTerm
107 N7885646763ed40fe850e3cf87306570e schema:name readcube_id
108 schema:value 4f8dd6d38b5348ae802a862450e05f0418acb3e4f2fc9d4658c21e7bd7bcaad5
109 rdf:type schema:PropertyValue
110 N82b4f42e847d432bbe59d351e8941b99 rdf:first sg:person.01213013520.94
111 rdf:rest N111243f8825a4f5a9789202f52d54102
112 N8a03979d391c473abc5143723d06f75a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Middle Aged
114 rdf:type schema:DefinedTerm
115 N8dea9f8d71974a229780889e8f241634 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antineoplastic Agents
117 rdf:type schema:DefinedTerm
118 N9928f03e0aa2452291acf472c84aac89 schema:issueNumber 2
119 rdf:type schema:PublicationIssue
120 N9b11b37a5bfb4e1389def6c67ad7fb92 rdf:first sg:person.01357677760.43
121 rdf:rest N6fb3ce40dd1e45038783e145198c39f1
122 Na36f02d5f1df4d01a9204717d3826e22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aged
124 rdf:type schema:DefinedTerm
125 Nacf435fc173d46ae908764f8de9ee683 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Gene Amplification
127 rdf:type schema:DefinedTerm
128 Nb16ce7e4384c47b0b70b045a2695363e rdf:first sg:person.01223342332.02
129 rdf:rest N11dcf2ccb0d642cb9a23a5f57870ad9c
130 Nb23213fe1b914becb1a28959b3f9d48f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Breast Neoplasms
132 rdf:type schema:DefinedTerm
133 Nb2ca9bf74355491fab28191b775977de schema:name nlm_unique_id
134 schema:value 8309330
135 rdf:type schema:PropertyValue
136 Nc49841940fa046efbcac4fe0b77fbb27 schema:name doi
137 schema:value 10.1007/s10637-008-9155-y
138 rdf:type schema:PropertyValue
139 Nc8b9b95ebf834fdb8e9eae11f1105630 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Retrospective Studies
141 rdf:type schema:DefinedTerm
142 Nd040af92174a449bac85a7160fdff292 schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 Ne6d632b2dbf74317ba30303928cbef98 schema:volumeNumber 27
145 rdf:type schema:PublicationVolume
146 Nfe7bc5d1dd1b425cb4b58825c8a2f7a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Trastuzumab
148 rdf:type schema:DefinedTerm
149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
150 schema:name Medical and Health Sciences
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
153 schema:name Oncology and Carcinogenesis
154 rdf:type schema:DefinedTerm
155 sg:journal.1094201 schema:issn 0167-6997
156 1573-0646
157 schema:name Investigational New Drugs
158 rdf:type schema:Periodical
159 sg:person.01203725612.04 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
160 schema:familyName Masci
161 schema:givenName Giovanna
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203725612.04
163 rdf:type schema:Person
164 sg:person.01213013520.94 schema:affiliation https://www.grid.ac/institutes/grid.4527.4
165 schema:familyName Torri
166 schema:givenName Valter
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213013520.94
168 rdf:type schema:Person
169 sg:person.01223342332.02 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
170 schema:familyName Gullo
171 schema:givenName Giuseppe
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223342332.02
173 rdf:type schema:Person
174 sg:person.01277354144.26 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
175 schema:familyName Santoro
176 schema:givenName Armando
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277354144.26
178 rdf:type schema:Person
179 sg:person.01357677760.43 schema:affiliation N236a578589d64f659d6d12fbefee0c5f
180 schema:familyName Salvini
181 schema:givenName Piermario
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357677760.43
183 rdf:type schema:Person
184 sg:person.0726433703.81 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
185 schema:familyName Bettio
186 schema:givenName Daniela
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726433703.81
188 rdf:type schema:Person
189 sg:pub.10.1023/a:1006111117877 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037590396
190 https://doi.org/10.1023/a:1006111117877
191 rdf:type schema:CreativeWork
192 sg:pub.10.1023/a:1006262324959 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047763314
193 https://doi.org/10.1023/a:1006262324959
194 rdf:type schema:CreativeWork
195 sg:pub.10.1038/sj.bjc.6602926 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012929330
196 https://doi.org/10.1038/sj.bjc.6602926
197 rdf:type schema:CreativeWork
198 sg:pub.10.1097/01.mp.0000052102.90815.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043809974
199 https://doi.org/10.1097/01.mp.0000052102.90815.82
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278910
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/j.ccr.2007.08.030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034133737
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/j.copbio.2007.11.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007493316
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/j.ejca.2006.11.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022644824
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejm200103153441101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031768583
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1093/annonc/mdj905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031702252
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1093/annonc/mdl475 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046368550
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/jnci/djk134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047572985
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1126/science.3798106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062621480
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1158/1078-0432.ccr-06-1304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049548242
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1200/jco.20.3.719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064202789
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1200/jco.2002.20.3.719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083941918
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.2005.04.173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003035955
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.2006.09.2775 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026719751
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.2007.14.8957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019255637
230 rdf:type schema:CreativeWork
231 https://doi.org/10.3816/cbc.2001.n.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003466394
232 rdf:type schema:CreativeWork
233 https://doi.org/10.3816/cbc.2005.n.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001198940
234 rdf:type schema:CreativeWork
235 https://www.grid.ac/institutes/grid.417728.f schema:alternateName Humanitas Research Hospital
236 schema:name Laboratory of Cytogenetics, Istituto Clinico Humanitas IRCCS, Rozzano, (Milan), Italy
237 Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.4527.4 schema:alternateName Mario Negri Institute for Pharmacological Research
240 schema:name Clinical Oncology Research Unit, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...